|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Epidemiology/Health Services/Psychosocial Research |
Transfer of Insulin Lispro Across the Human Placenta
In vitro perfusion studies
1 Division of Clinical Pharmacology and Toxicology, the Hospital for Sick Children, Toronto, Ontario, Canada
2 Department of Endocrinology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
OBJECTIVE—Insulin lispro (Humalog), a human insulin analog, has a more rapid onset, earlier peak, and shorter duration of glucose lowering activity than regular human insulin. However, it is not known whether insulin lispro crosses the human placenta and reaches the fetus. Therefore, the objective of the present study was to examine whether insulin lispro crosses the placenta using the technique of perfusing a human placental lobule in vitro.
RESEARCH DESIGN AND METHODS—Term human placentae from uncomplicated pregnancies were obtained immediately after delivery. Insulin lispro, at concentrations ranging from 100 to 1000 µU/ml, was introduced into the maternal reservoir. The maternal side of the placenta was perfused with constant concentration of lispro insulin; the fetal circulation was closed. Samples were drawn from both the maternal and fetal circulations at regular intervals. The appearance of insulin lispro in the fetal circulation was analyzed by a specific radioimmunoassay.
RESULTS—No placental transfer of lispro could be detected during perfusion with 100 and 200 µU/ml. In contrast, there was a small concentration-dependent transfer to the fetus at concentrations of 580 µU/ml and higher, detectable after at least an hour of constant concentration of insulin lispro during perfusion. The rate of placental transfer was 0.019 µU · min-1 · g tissue-1 at maternal levels of 580 µU/ml and 0.045 µU · min-1 · g-1 tissue at maternal levels of 1000 µU/ml. Measuring lispro levels in 11 pregnant women revealed that a dose of 50 units may achieve serum concentrations >200 µU/ml with apparent linear correlation between dose and levels.
CONCLUSIONS—Insulin lispro is not likely to cross the placenta at a single standard dose. This study suggests that insulin lispro is unlikely to reach or harm the unborn baby.
Abbreviations: hCG, human chorionic gonadotrophin
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. R. Coustan A 40-Year-Old Woman With Diabetes Contemplating Pregnancy After Gastric Bypass Surgery JAMA, June 4, 2008; 299(21): 2550 - 2557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Jovanovic and D. J. Pettitt Treatment With Insulin and Its Analogs in Pregnancies Complicated by Diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S220 - S224. [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Trujillo Insulin Analogs and Pregnancy Diabetes Spectr, April 1, 2007; 20(2): 94 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Woolderink, A. J. van Loon, F. Storms, L. de Heide, and K. Hoogenberg Use of Insulin Glargine During Pregnancy in Seven Type 1 Diabetic Women Diabetes Care, October 1, 2005; 28(10): 2594 - 2595. [Full Text] [PDF]
|
|
|
|
|
|
M. Dolci, M. Mori, and F. Baccetti Use of Glargine Insulin Before and During Pregnancy in a Woman With Type 1 Diabetes and Addison's Disease Diabetes Care, August 1, 2005; 28(8): 2084 - 2085. [Full Text] [PDF]
|
|
|
|
 |
|
 I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ahmad Review: Pharmacology of insulin The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 10 - 14. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |